Literature DB >> 26503642

Delayed diagnosis leading to accelerated-phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive TNIP1-PDFGRB fusion gene.

D M Ross1,2,3, H K Altamura4, C N Hahn3,4,5, M Nicola4, A L Yeoman4, M R Holloway4, J Geoghegan6, J Feng5,6,7, A W Schreiber5,6,7, S Branford4,5,8, S Moore4, H S Scott3,4,5,6,7,8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26503642     DOI： 10.1038/leu.2015.301

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  STAR: ultrafast universal RNA-seq aligner.

Authors:  Alexander Dobin; Carrie A Davis; Felix Schlesinger; Jorg Drenkow; Chris Zaleski; Sonali Jha; Philippe Batut; Mark Chaisson; Thomas R Gingeras
Journal:  Bioinformatics       Date:  2012-10-25       Impact factor: 6.937

2.  Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness.

Authors:  Amy D Klion; Pierre Noel; Cem Akin; Melissa A Law; D Gary Gilliland; Jan Cools; Dean D Metcalfe; Thomas B Nutman
Journal:  Blood       Date:  2003-04-03       Impact factor: 22.113

3.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.

Authors:  Giulio Genovese; Anna K Kähler; Robert E Handsaker; Johan Lindberg; Samuel A Rose; Samuel F Bakhoum; Kimberly Chambert; Eran Mick; Benjamin M Neale; Menachem Fromer; Shaun M Purcell; Oscar Svantesson; Mikael Landén; Martin Höglund; Sören Lehmann; Stacey B Gabriel; Jennifer L Moran; Eric S Lander; Patrick F Sullivan; Pamela Sklar; Henrik Grönberg; Christina M Hultman; Steven A McCarroll
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

4.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Authors:  Jan Cools; Daniel J DeAngelo; Jason Gotlib; Elizabeth H Stover; Robert D Legare; Jorges Cortes; Jeffrey Kutok; Jennifer Clark; Ilene Galinsky; James D Griffin; Nicholas C P Cross; Ayalew Tefferi; James Malone; Rafeul Alam; Stanley L Schrier; Janet Schmid; Michal Rose; Peter Vandenberghe; Gregor Verhoef; Marc Boogaerts; Iwona Wlodarska; Hagop Kantarjian; Peter Marynen; Steven E Coutre; Richard Stone; D Gary Gilliland
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

Review 5.  Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders.

Authors:  Andreas Reiter; Christoph Walz; Nicholas C P Cross
Journal:  Curr Drug Targets       Date:  2007-02       Impact factor: 3.465

6.  Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.

Authors:  Raajit Rampal; Jihae Ahn; Omar Abdel-Wahab; Michelle Nahas; Kai Wang; Doron Lipson; Geoff A Otto; Roman Yelensky; Todd Hricik; Anna Sophia McKenney; Gabriela Chiosis; Young Rock Chung; Suveg Pandey; Marcel R M van den Brink; Scott A Armstrong; Ahmet Dogan; Andrew Intlekofer; Taghi Manshouri; Christopher Y Park; Srdan Verstovsek; Franck Rapaport; Philip J Stephens; Vincent A Miller; Ross L Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-02       Impact factor: 11.205

7.  RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.

Authors:  Jason H Mendler; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Heiko Becker; Klaus H Metzeler; Sebastian Schwind; Susan P Whitman; Jihane Khalife; Jessica Kohlschmidt; Deedra Nicolet; Bayard L Powell; Thomas H Carter; Meir Wetzler; Joseph O Moore; Jonathan E Kolitz; Maria R Baer; Andrew J Carroll; Richard A Larson; Michael A Caligiuri; Guido Marcucci; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2012-07-02       Impact factor: 44.544

8.  Critical role of the platelet-derived growth factor receptor (PDGFR) beta transmembrane domain in the TEL-PDGFRbeta cytosolic oncoprotein.

Authors:  Federica Toffalini; Carina Hellberg; Jean-Baptiste Demoulin
Journal:  J Biol Chem       Date:  2010-02-17       Impact factor: 5.157

9.  Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.

Authors:  M Schmidt; J Rinke; V Schäfer; S Schnittger; A Kohlmann; E Obstfelder; C Kunert; J Ziermann; N Winkelmann; E Eigendorff; T Haferlach; C Haferlach; A Hochhaus; T Ernst
Journal:  Leukemia       Date:  2014-09-12       Impact factor: 11.528

10.  A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone.

Authors:  C N Hahn; D M Ross; J Feng; A Beligaswatte; D K Hiwase; W T Parker; M Ho; M Zawitkowski; K L Ambler; G D Cheetham; Y K Lee; M Babic; C M Butcher; G A Engler; A L Brown; R J D'Andrea; I D Lewis; A W Schreiber; L B To; H S Scott
Journal:  Leukemia       Date:  2015-03-09       Impact factor: 11.528
View more
  3 in total

Review 1.  Interstitial Deletions Generating Fusion Genes.

Authors:  Ioannis Panagopoulos; Sverre Heim
Journal:  Cancer Genomics Proteomics       Date:  2021 May-Jun       Impact factor: 4.069

2.  PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.

Authors:  Yingchi Zhang; Yufeng Gao; Hui Zhang; Jingliao Zhang; Fuhong He; Aleš Hnízda; Maoxiang Qian; Xiaoming Liu; Yoshihiro Gocho; Ching-Hon Pui; Tao Cheng; Qianfei Wang; Jun J Yang; Xiaofan Zhu; Xin Liu
Journal:  Blood       Date:  2018-02-06       Impact factor: 25.476

Review 3.  PDGFRᵝ-Rearranged Myeloid Neoplasm with Marked Eosinophilia in a 37-Year-Old Man; And a Literature Review.

Authors:  Mirela Andrei; Andrei Bandarchuk; Cherif Abdelmalek; Ajay Kundra; Vladimir Gotlieb; Jen Chin Wang
Journal:  Am J Case Rep       Date:  2017-02-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.